

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**TARGET INSURANCE (HOLDINGS) LIMITED**  
**泰加保險(控股)有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock code: 6161)**

**SECOND MODIFIED RESUMPTION GUIDANCE AND  
CONTINUED SUSPENSION OF TRADING**

This announcement is made by Target Insurance (Holdings) Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated (i) 5 January 2022 in relation to suspension of trading in the shares of the Company on the Stock Exchange; (ii) 20 January 2022 and 17 February 2022 in relation to the resumption guidance for the Company imposed by the Stock Exchange (the “**Initial Resumption Guidance**”); and (iii) 7 April 2022 in relation to the modified resumption guidance for the Company imposed by the Stock Exchange (the “**First Modified Resumption Guidance**”) (the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings defined under the Announcements.

## SECOND MODIFIED RESUMPTION GUIDANCE

The Company has received a letter (the “**Letter**”) from the Stock Exchange on 24 April 2023. The Letter makes reference to the Announcements and sets out the following modified resumption guidance (the “**Second Modified Resumption Guidance**”, together with the Initial Resumption Guidance and the First Modified Guidance, the “**Resumption Guidance**”) for the resumption of trading in the shares of the Company:

- demonstrate that there is no reasonable regulatory concern about management integrity and/or the integrity of any persons with the substantial influence over the Company’s management and operations, which may pose a risk to investors and damage market confidence.

For completeness, the latest Resumption Guidance for the Company is set out as follows:

- (i) demonstrate its compliance with Rule 13.24 of the Listing Rules;
- (ii) demonstrate its compliance with Rules 3.10, 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules;
- (iii) publish all outstanding financial results and address any audit modifications;
- (iv) inform the market of all material information for the Company’s shareholders and investors to appraise the Company’s position; and
- (v) demonstrate that there is no reasonable regulatory concern about management integrity and/or the integrity of any persons with the substantial influence over the Company’s management and operations, which may pose a risk to investors and damage market confidence.

The Stock Exchange indicated that it may modify the Resumption Guidance and/or give further guidance if the Company’s situation changes.

The Company is taking appropriate steps to resolve the outstanding issues causing its trading suspension and will seek to resume trading of its shares as soon as possible. The Company will keep its shareholders and potential investors informed of the latest progress as and when appropriate and will announce quarterly updates on its development pursuant to Rule 13.24A of the Listing Rules.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 5 January 2022 and will remain suspended until further notice.

By order of the Board  
**Target Insurance (Holdings) Limited**  
**Dr. Ng Yu**  
*Chairman*

Hong Kong, 28 April 2023

*As at the date of this announcement, the board of directors of the Company comprises one executive Director, namely Ms. Liang Qin; two non-executive Directors, namely, Dr. Ng Yu (Chairman) and Mr. Ling Xujun; and three independent non-executive Directors, namely Mr. He Xiaobin, Mr. Chiam Tat Yiu, and Mr. Yu Cho Tak.*